Indoles, 1H-indazoles, 1,2-benzisoxazoles, and...

Details Indoles, 1H-indazoles, 1,2-benzisoxazoles, and... Indoles, 1H-indazoles, 1,2-benzisoxazoles, and...

2008-07-08

2008-07-08

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S365000, C514S374000, C514S414000, C544S349000, C548S181000, C548S236000, C548S362500

Reexamination Certificate

active

11018429

ABSTRACT:
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

REFERENCES:
patent: 4605652 (1986-08-01), Welstead et al.
patent: 4775668 (1988-10-01), Jefson
patent: 4789673 (1988-12-01), Donatsch et al.
patent: 4798829 (1989-01-01), King et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4886808 (1989-12-01), King
patent: 4895943 (1990-01-01), Friedmann
patent: 4910193 (1990-03-01), Buchheit
patent: 4910207 (1990-03-01), Donatsch et al.
patent: 4937247 (1990-06-01), King
patent: 4942160 (1990-07-01), Sanger et al.
patent: 4975436 (1990-12-01), Tyers
patent: 4985424 (1991-01-01), van Wijngaarden et al.
patent: 5017582 (1991-05-01), Donatsch
patent: 5034398 (1991-07-01), King
patent: 5063231 (1991-11-01), Sanger et al.
patent: 5098889 (1992-03-01), Costall et al.
patent: 5098909 (1992-03-01), Williams
patent: 5192770 (1993-03-01), Clark et al.
patent: 5204356 (1993-04-01), Tyers
patent: 5223625 (1993-06-01), Van Wijngaarden et al.
patent: 5272154 (1993-12-01), Dixon et al.
patent: 5273972 (1993-12-01), Jagdmann et al.
patent: 5446050 (1995-08-01), Rosen
patent: 5543426 (1996-08-01), Dixon et al.
patent: 5561149 (1996-10-01), Azria et al.
patent: 5641802 (1997-06-01), Arcamone et al.
patent: 5679673 (1997-10-01), Brown et al.
patent: 5773436 (1998-06-01), Muller et al.
patent: 5952363 (1999-09-01), Kristiansen et al.
patent: 5985866 (1999-11-01), Muller et al.
patent: 6492385 (2002-12-01), Myers et al.
patent: 6500840 (2002-12-01), Myers et al.
patent: 6599916 (2003-07-01), Myers et al.
patent: 6624173 (2003-09-01), Crooks et al.
patent: 6780861 (2004-08-01), Nozulak
patent: 6828330 (2004-12-01), Walker et al.
patent: 6849620 (2005-02-01), Walker et al.
patent: 6911543 (2005-06-01), Walker et al.
patent: 7001900 (2006-02-01), Jacobsen et al.
patent: 2002/0086871 (2002-07-01), O'Neill et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2003/0073707 (2003-04-01), Walker et al.
patent: 2004/0002513 (2004-01-01), Mazurov et al.
patent: 2005/0182062 (2005-08-01), Galli et al.
patent: 2005/0209236 (2005-09-01), Hendrix et al.
patent: 2006/0014750 (2006-01-01), O'Donnell et al.
patent: 2 361 437 (1988-03-01), None
patent: 10 305 922 (2004-03-01), None
patent: 0013138 (1980-07-01), None
patent: 0 200 444 (1986-11-01), None
patent: 0 214 772 (1987-03-01), None
patent: 0 279 512 (1988-08-01), None
patent: 0 377 238 (1990-07-01), None
patent: 0 498 466 (1992-08-01), None
patent: 0 261 964 (1998-03-01), None
patent: 1 079 828 (2001-03-01), None
patent: 1 219 622 (2002-07-01), None
patent: 1219622 (2002-07-01), None
patent: 1 235 826 (2002-09-01), None
patent: 2 548 666 (1985-01-01), None
patent: 2 125 398 (1984-03-01), None
patent: 2 145 416 (1985-03-01), None
patent: 2002-30084 (2002-01-01), None
patent: WO 84/00166 (1984-01-01), None
patent: WO 85/01048 (1985-03-01), None
patent: WO 90/14347 (1990-11-01), None
patent: WO 91/09593 (1991-07-01), None
patent: WO 92/12149 (1992-07-01), None
patent: WO 93/08185 (1993-04-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 0058311 (2000-10-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 01/90109 (2001-11-01), None
patent: 01/92260 (2001-12-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 02/36114 (2002-05-01), None
patent: WO 02/085901 (2002-10-01), None
patent: WO 00/45846 (2002-12-01), None
patent: WO 02/096911 (2002-12-01), None
patent: WO 02/100833 (2002-12-01), None
patent: WO 02/100857 (2002-12-01), None
patent: WO 02/100858 (2002-12-01), None
patent: WO 03/022856 (2003-03-01), None
patent: WO 03/029252 (2003-04-01), None
patent: WO 03 037896 (2003-05-01), None
patent: WO 03/042210 (2003-05-01), None
patent: WO 03/51874 (2003-06-01), None
patent: WO 03/070731 (2003-08-01), None
patent: WO 03/072578 (2003-09-01), None
patent: WO 03/078431 (2003-09-01), None
patent: WO 03/080606 (2003-10-01), None
patent: WO 03/094830 (2003-11-01), None
patent: WO 03/101987 (2003-11-01), None
patent: WO 04/014864 (2004-02-01), None
patent: WO 04/016616 (2004-02-01), None
patent: WO 04/016617 (2004-02-01), None
patent: WO 014922 (2004-02-01), None
patent: WO 04/033456 (2004-04-01), None
patent: WO 05/01299 (2005-02-01), None
STN International, p. 5 (2006).
Sacco et al., “Nicotinic Receptor Mechanisms and Cognition in Normal Sates and Neuropsychiatric Disorders,” J. Psychopharmacol., 18(4) pp. 457-474 (2004).
Charpantier et al., α7 Neuronal Nicotinic Acetylcholine Receptors Are Negatively Regulated by Tyrosine Phosporylation and Src-Family Kinases, J. of Neuroscience, 25(43), pp. 9836-9849 (2005).
Sacco et al., “Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorder,” J. Psychopharmacol., Dec. 18, 2004(4) 457-474.
Zaniewska et al., “Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats,” Europenan J. Pharmacol. 540 (2006) 96-106.
T. van Herk, et al., “Pyrazole Derivatives as Partial Agonists for the Nicotinic Acid Receptor,” J. Med. Chem. 2003, 46, 3945-3951.
S.M. Evans et al., “Probing the 5-HT3Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives”, Med. Chem. Res. (1993), 3:386-406.
D. Flammia, “Lobeline: Structure-Affinity Investigation of Nicotinic Acetylcholinergic Receptor Binding”, J. Med. Chem. (1999), 42:3726-2731.
R. Azuma et al. “Metabolism and Disposition of GTS-21, A Novel Drug for Alzheimer's Disease”, Xenobiotica (1999), vol. 29, No. 7, pp. 747-762.
K. E. Stevens. Et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice”, Psychopharmacology (1998), 136:320-327.
R. Azuma et al., “The effect of repeat administration of GTS-21 on mixed-function oxidase activities in rat”, Elsevier Science Ireland Ltd., Toxicology Letters 110 (1999) pp. 137-144.
M. Decker, et al., “Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for CNS Therapeutics”, 2000, pp. 1-14.
M. W. Holladay et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery”, Journal of Medicinal Chemistry, vol. 40, No. 26, (1997), pp. 4169-4194.
Astles et al., Current Drug Targets—CNS Neurological Disorders, 2002, 1, pp. 337-348.
Mazurov et al., Biorg. & Med. Chem. Lett., 2005, No. 1 15, pp. 2073-2077.
Bermudez et al., J. Med. Chem., 1990, 33, 1924-1929.
Int'l. Search Report and the Written Opinion of the Int'l. Searching Authority, issued Jun. 16, 2005 in PCT/US2004/042852.
Nurhrich et al., Eur. J. Med. Chem. 1996, No. 31, pp. 957-964.

Affiliated with

Also associated with

Rating

Indoles, 1H-indazoles, 1,2-benzisoxazoles, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indoles, 1H-indazoles, 1,2-benzisoxazoles, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indoles, 1H-indazoles, 1,2-benzisoxazoles, and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3913961